Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00067028 · ClinicalTrials.gov registry record · Phase 2
Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
NCT00067028: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00067028 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 116 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00067028, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
Study Summary
The goal is to compare the drug combinations clofarabine/idarubicin/ara-C, clofarabine/ara-C, and clofarabine/idarubicin in the treatment of patients with Acute Myeloid Leukemia, high-grade MDS, or myeloid blast phase of Chronic Myeloid Leukemia who have relapsed following their initial therapy.
Interventions
- DRUG Clofarabine 40mg/m^2
- DRUG Idarubicin 10mg/m^2
- DRUG Ara-C 0.75 g/m^2
- DRUG Clofarabine 22.5mg/m^2
- DRUG Ara-C 1 g/m^2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2003-12 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00067028
The ClinicalTrials.gov registry entry for NCT00067028 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Clofarabine 40mg/m^2 is the first listed.
NCT00067028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00067028 about?
NCT00067028 is a clinical study titled "Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)". The goal is to compare the drug combinations clofarabine/idarubicin/ara-C, clofarabine/ara-C, and clofarabine/idarubicin in the treatment of patients with Acute Myeloid Leukemia, high-grade MDS, or myeloid blast phase of Chronic Myeloid Leukemia who have relapsed following their initial therapy.
What is the current status of trial NCT00067028?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2003-12. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00067028?
The interventions under investigation include: Clofarabine 40mg/m^2 (DRUG), Idarubicin 10mg/m^2 (DRUG), Ara-C 0.75 g/m^2 (DRUG), Clofarabine 22.5mg/m^2 (DRUG), Ara-C 1 g/m^2 (DRUG).
Who is sponsoring clinical trial NCT00067028?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.